View Cesca’s Vision for the Future of its SurgWerks Platform for Point of Care Regenerative Medicine.
Initial concept for SurgWerks platform, designed for use in surgical suites for bone marrow collection, processing and delivery.
Cesca’s AutoXpress® Technology for Cord Blood Processing and Preservation
An overview of the form and function of the AutoXpress bioprocessing and BioArchive® cryopreservation
Forward Looking Statements
These videos contains forward-looking statements. Such forward-looking statements include but are not limited to our cell therapy clinical trial targets, development costs, projected timelines etc. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including the timing of FDA and foreign regulatory approvals as to products, changes in customer forecasts, our ability to meet customers’ purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers’ products, introduction timing and acceptance of our new products, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption “Risk Factors” in our proxy statement/prospectus/consent solicitation and other reports we file with the SEC from time to time, and you should consider each of those factors when evaluating the forward-looking statements.